Viking Ther­a­peu­tics taps Cor­den­Phar­ma to man­u­fac­ture its obe­si­ty drugs

Viking Ther­a­peu­tics has con­tract­ed CD­MO Cor­den­Phar­ma for a to­tal of $150 mil­lion to make bil­lions of clin­i­cal and com­mer­cial dos­es of its GLP-1/GIP re­cep­tor ag­o­nist …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER